PCH
NAMS icon

Polar Capital Holdings’s NewAmsterdam Pharma NAMS Stock Holding History

Polar Capital Holdings’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-909,742
Closed -$10.2M – 299
2023
Q4 		$10.2M Buy
+909,742
New +$8.33M 0.06% 196

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Polar Capital Holdings's NAMS Position: Q1 2026 in Review

Polar Capital Holdings increased its NewAmsterdam Pharma (NAMS) stake by 2% in Q1 2026, buying an estimated $1.8M and bringing the position to 2,831,607 shares worth $90.6M. The position accounts for 0.32% of the portfolio, ranked #68.

Polar Capital Holdings first reported a position in NAMS in Q1 2024 and has held it in 9 quarters since. The position peaked at $97.4M in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Polar Capital Holdings held 2,831,607 shares of NewAmsterdam Pharma worth $90.6M as of Q1 2026.
  • Polar Capital Holdings bought 55,385 NewAmsterdam Pharma shares in Q1 2026, an estimated $1.8M.
  • NewAmsterdam Pharma made up 0.32% of Polar Capital Holdings's portfolio in Q1 2026, its #68 holding.
  • Polar Capital Holdings first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 9 quarters since.
  • Polar Capital Holdings's NewAmsterdam Pharma position peaked at $97.4M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.